IBD Surgery & Perioperative Management
Module Overview
Surgical indications, perioperative medication management, IPAA/pouch surgery, strictureplasty, and post-surgical complications including pouchitis.
Benchmark Source: ECCO Surgery Module + Johns Hopkins Surgical IBD Rotation
Learning Objectives
Identify surgical indications in UC (refractory, dysplasia, cancer) and CD (stricture, fistula, abscess)
Manage perioperative biologic and immunomodulator timing
Diagnose and manage pouchitis, cuffitis, and Crohn's of the pouch
Counsel patients on surgical options and quality-of-life outcomes
Teaching Sessions
Surgical Indications & Optimal Timing in IBD
Evidence-based approach to surgical indications in UC and Crohn's, timing of surgery, and shared decision-making frameworks.
1UC Surgical Indications: Emergency vs Elective
Emergency/urgent UC surgery: (1) toxic megacolon with impending or actual perforation, (2) massive colonic hemorrhage requiring >6 units PRBC/24h, (3) ASUC failing medical rescue within 3–7 days (per Oxford criteria + failed salvage), (4) colonic perforation. Elective indications: (1) medically refractory chronic active UC despite optimized therapy (biologics/small molecules), (2) medication-intolerance preventing disease control, (3) confirmed dysplasia or cancer (HGD or invisible multifocal LGD, non-resectable visible dysplasia, CRC), (4) growth failure in pediatric patients, (5) patient preference after informed discussion of surgical alternative. Timing principle: avoid emergency surgery whenever possible—morbidity and mortality are 2–3× higher than elective. In Saudi tertiary practice, optimize nutrition (prealbumin, albumin >30 g/L target), reduce steroids (<20 mg prednisolone/day if possible), control sepsis, and consult enterostomal therapy before elective surgery.
The single best predictor of operative morbidity is preoperative steroid dose >20 mg prednisolone. If elective surgery can wait 4–8 weeks, use that window to taper steroids, optimize nutrition, and bridge with a biologic that does not increase surgical complications (infliximab has no consistent negative signal despite historical concern).
- Emergency: toxic megacolon, perforation, hemorrhage, failed ASUC rescue
- Elective: refractory disease, intolerance, dysplasia/cancer, growth failure
- Emergency surgery morbidity is 2–3× elective—delay when possible
- Optimize: steroids <20 mg, albumin >30, nutrition, sepsis control
- Enterostomal therapy consult before elective surgery
2Crohn's Surgical Indications: Disease Pattern Drives Approach
Unlike UC, Crohn's surgery is not curative—aim is to address complications and preserve bowel length. Indications: (1) stricturing disease with symptoms refractory to medical/endoscopic therapy; (2) penetrating disease (intra-abdominal fistula, entero-enteric, entero-vesical, entero-vaginal, entero-cutaneous) with symptoms; (3) abscess >3 cm not amenable to percutaneous drainage, or recurrent despite drainage; (4) localized ileocecal disease with preference for surgery-first approach (LIR!C trial: laparoscopic ileocecal resection noninferior to infliximab for induction, better QoL at 12 months, similar costs over 5 years); (5) dysplasia/cancer in colonic Crohn's; (6) growth failure in children; (7) colonic strictures not amenable to EBD; (8) perforation. Bowel-sparing principles: resection limited to grossly diseased segment with 2 cm margins; strictureplasty (Heineke-Mikulicz for short <10 cm, Finney 10–20 cm, Michelassi >20 cm) for multiple strictures to preserve length; avoid extensive resections that risk short bowel syndrome. Kono-S anastomosis (antimesenteric, functional end-to-end with mesenteric preservation) reduces anastomotic recurrence vs conventional side-to-side or end-to-end (SUPREME-CD trial).
The LIR!C trial changed practice: for short-segment ileocecal Crohn's failing 5-ASA/steroids, laparoscopic resection is a legitimate first-line alternative to infliximab, with similar 5-year outcomes and potentially better quality of life. Discuss this option with young patients facing biologic commitment.
- Crohn's surgery is palliative, not curative; bowel-sparing essential
- LIR!C: laparoscopic ileocecal resection noninferior to infliximab first-line
- Strictureplasty (Heineke-Mikulicz, Finney, Michelassi) for multifocal
- Kono-S anastomosis reduces recurrence vs side-to-side
- 2 cm margins adequate; avoid extensive resection → short bowel
3Shared Decision-Making & Patient Preparation
Every elective IBD surgery decision should involve structured shared decision-making: (1) review disease course, medication history, and current trajectory; (2) explicitly discuss surgery as a treatment option, not a failure; (3) present realistic outcomes (QoL, function, recurrence risk, pouch function for UC, recurrence risk for Crohn's); (4) address patient concerns (body image, stoma adaptation, sexuality, fertility, pregnancy, work, travel—Hajj/Umrah considerations for Saudi patients); (5) involve family appropriately per cultural norms; (6) decision aids (video, booklet, peer patient contact) improve informed consent. Patient preparation includes: (a) enterostomal therapy consult with stoma site marking even if pouch planned (backup end ileostomy may be needed), (b) nutrition optimization (5–10% weight loss in 6 months is malnutrition—consider preoperative EEN or TPN if severe), (c) anemia optimization (IV iron, rarely transfusion), (d) VTE risk assessment with perioperative prophylaxis plan, (e) medication review (hold/adjust per surgical team: methotrexate OK; thiopurines OK; biologics usually continued through surgery based on dosing intervals; JAK inhibitors stop 1–2 weeks before elective surgery per vascular risk concerns). Saudi patients may have specific concerns about Hajj/Umrah with a stoma—provide written guidance on pouch management during ihram and travel.
Offer peer support: connect patients with others who have undergone IPAA or ileostomy. Saudi IBD patient groups (Sanad, Twasul) facilitate peer connections. Culturally, family involvement in decision-making is important—invite spouse/parents to the consultation with patient's consent. Provide Arabic-language stoma education materials.
- Frame surgery as treatment option, not failure
- Pre-op stoma marking by enterostomal therapy for all colonic IBD surgeries
- Optimize nutrition, anemia, VTE prophylaxis, medication holds
- Address Saudi-specific concerns: Hajj/Umrah, family role, Arabic materials
- Peer support via Saudi IBD patient groups (Sanad, Twasul)
- Emergency UC surgery: toxic megacolon, perforation, hemorrhage, failed rescue
- LIR!C supports surgery as first-line option for short-segment ileocecal Crohn's
- Optimize steroids, nutrition, anemia before elective surgery
- Kono-S anastomosis reduces Crohn's recurrence vs conventional
- Shared decision-making with Saudi cultural framing (family, Hajj, peer support)
Perioperative Management of IBD Medications
Evidence and guidelines for holding, continuing, or adjusting IBD therapies around surgery; ERAS principles in IBD surgery.
1Biologics & Small Molecules Perioperatively
Historical concern that biologics (especially anti-TNF) increase postoperative infection has largely been refuted by recent high-quality data: meta-analyses and the PUCCINI prospective cohort show no consistent increase in 30-day infection, anastomotic leak, or total complications with preoperative infliximab, adalimumab, vedolizumab, or ustekinumab in UC or Crohn's surgery. ACG/AGA/ECCO guidelines: continue biologics through surgery without dose adjustment; schedule elective surgery when convenient, not based on last dose. JAK inhibitors (tofacitinib, upadacitinib) and S1P modulators (ozanimod, etrasimod): evidence is more limited and concern about VTE/cardiovascular events + effect on lymphocyte trafficking warrants holding 1–2 weeks before elective surgery (ASGE/ACG expert opinion). Corticosteroids: dose-dependent risk—stress-dose perioperative hydrocortisone for chronic >5 mg prednisolone/day; risk of anastomotic leak rises sharply at >20 mg prednisolone. 5-ASA agents: continue without interruption. Thiopurines/methotrexate: continue. Post-op restart timing: biologics can generally restart on schedule if no infection; hold if active surgical site infection or open wound until resolved.
Do not delay surgery to "wash out" biologics—modern evidence supports continuation. Exception: JAK inhibitors should be stopped because of their short half-life, rapid offset allowing tapering, and theoretical VTE/cardiovascular concerns in the perioperative state. Communicate clearly to the surgical team what medications the patient is on and expected return schedule.
- Continue biologics through elective surgery (no evidence of harm)
- Hold JAK inhibitors and S1P modulators 1–2 weeks preop
- Taper steroids to <20 mg prednisolone if possible; stress-dose >5 mg
- Continue 5-ASA, thiopurines, methotrexate perioperatively
- Restart biologics on schedule post-op if no infection
2ERAS in IBD Surgery
Enhanced Recovery After Surgery (ERAS) protocols reduce length of stay, complications, and cost. Key IBD-specific ERAS elements: (1) preoperative carbohydrate loading 2 h before surgery (unless diabetic); (2) no mechanical bowel prep for small bowel surgery; for colectomy, oral antibiotics + mechanical prep debated but current consensus favors combined approach; (3) early mobilization within 6 h post-op; (4) early enteral nutrition (clear fluids within 12 h, solid food within 24–48 h); (5) minimally invasive surgery (laparoscopic/robotic) when feasible—reduces pain, ileus, and length of stay; (6) multimodal analgesia avoiding opioid excess; (7) avoidance of NG tube routine use; (8) early Foley removal (within 24 h); (9) VTE prophylaxis (low molecular weight heparin, prolonged if major pelvic surgery or cancer). Saudi tertiary centers (KFSHRC, KAMC, KFMC) have ERAS protocols; implementation reduces LOS from 7–9 days to 4–6 days in IBD surgery. Audit local compliance and outcomes.
Track ERAS compliance as a quality metric. Common gaps in Saudi centers include delayed enteral nutrition (persistence of "NPO until flatus" culture) and prolonged NG tubes. Champion early feeding—patients tolerate clear fluids within 6–12 h after colonic surgery, and bowel function returns faster.
- ERAS reduces LOS from 7–9 to 4–6 days in IBD surgery
- Carb loading 2h pre-op; no mechanical prep for SB surgery
- Early mobilization (6h), early feeding (12–24h), laparoscopic when feasible
- Multimodal analgesia; avoid NG routinely; early Foley removal
- Extended LMWH VTE prophylaxis for pelvic/cancer cases
3VTE Prophylaxis, Nutrition, Anemia
IBD patients have 3–4× increased VTE risk vs non-IBD; postoperative risk further elevated. Routine VTE prophylaxis with LMWH (enoxaparin 40 mg SC daily or 30 mg BID for high-risk) should start preoperatively and continue 7–10 days post-op for routine cases, extended to 28 days for major pelvic/abdominal surgery or cancer. Mechanical prophylaxis (sequential compression) as adjunct. Nutrition: preoperative malnutrition (albumin <30 g/L, weight loss >10%) is a strong predictor of complications—consider 2–4 weeks preoperative EEN (exclusive enteral nutrition) or supplemental parenteral nutrition if severe. Anemia: iron deficiency common in IBD; intravenous iron (ferric carboxymaltose, iron isomaltoside) 1–2 weeks pre-op restores hemoglobin faster than oral; transfusion only for symptomatic or Hb <7 g/dL. Address B12, folate, vitamin D, zinc deficiencies. Smoking cessation at least 4 weeks before elective surgery; address post-op risk. Saudi context: address Ramadan fasting considerations if surgery planned near Ramadan—most IBD patients with active disease or recent surgery are exempt from fasting, but provide documented guidance.
Extended VTE prophylaxis for 28 days post-op (vs 7–10 days) reduces VTE events by ~50% in IBD abdominal surgery per meta-analyses. Despite out-of-hospital LMWH cost, it's cost-effective. Ensure Saudi patients have access to home injection training or alternative (rivaroxaban has emerging data for extended prophylaxis).
- LMWH prophylaxis pre-op and 7–10d post-op routine; 28d for pelvic/cancer
- Pre-op EEN 2–4 weeks if malnourished (albumin <30, weight loss >10%)
- IV iron 1–2 weeks pre-op for iron-deficiency anemia
- Address B12, folate, vitamin D, zinc; smoking cessation 4 weeks
- Saudi: Ramadan fasting exemption guidance for active/recent-surgery patients
- Continue biologics through surgery; hold JAK/S1P 1–2 weeks preop
- Steroids >20 mg prednisolone sharply increase anastomotic leak risk
- ERAS protocols reduce LOS, complications, and cost in IBD surgery
- Extended VTE prophylaxis (28d) for pelvic/cancer IBD surgery
- Address Saudi-specific: Ramadan, family role, home LMWH access
IPAA (J-Pouch) Surgery & Long-Term Management
Ileal pouch–anal anastomosis for UC: staging strategies, pouch anatomy, common pouch disorders, and chronic management.
1IPAA Staging & Technical Considerations
IPAA is the reconstructive option after total proctocolectomy in UC, preserving continence. Staging approaches: (1) 3-stage: total abdominal colectomy with end ileostomy first (emergent or for ASUC), proctectomy + IPAA + loop ileostomy second, loop ileostomy closure third; (2) 2-stage: proctocolectomy + IPAA + loop ileostomy, then closure—standard for elective; (3) modified 2-stage: colectomy first, then proctectomy + IPAA without diverting ileostomy (in selected, well-optimized patients). Pouch configurations: J-pouch (most common, 2 limbs, ~15 cm reservoir), S-pouch (3 limbs, for short mesentery), W-pouch (4 limbs, largest reservoir)—J is standard. Anastomosis: stapled IPAA (retains 1–2 cm cuff of rectal mucosa, technically easier, preserves continence better) vs hand-sewn IPAA with mucosectomy (removes all rectal mucosa, preferred for dysplasia/cancer, lower continence). Minimally invasive approach (laparoscopic, robotic) now preferred when feasible. Early complications: pelvic sepsis, anastomotic leak, pouch failure (5–10% lifetime), bowel obstruction. The "cuff" of residual rectal mucosa (stapled approach) requires annual surveillance for dysplasia/cancer, especially in UC with prior colonic dysplasia.
For patients with known colonic dysplasia or CRC in the proctectomy specimen, perform hand-sewn IPAA with mucosectomy to eliminate residual at-risk rectal mucosa. For straightforward UC without dysplasia, stapled IPAA gives better functional outcomes—most Saudi tertiary centers use stapled as default with cuff surveillance.
- J-pouch standard; S/W for selected anatomic constraints
- 3-stage for emergency/ASUC; 2-stage elective; modified 2-stage selected
- Stapled IPAA (better function, cuff surveillance) vs hand-sewn (mucosectomy)
- Minimally invasive (laparoscopic/robotic) when feasible
- Cuff requires annual surveillance for dysplasia in stapled approach
2Pouchitis: Acute, Chronic, Classification
Pouchitis is the most common long-term complication (50% by 5 years, 75% lifetime). Classification: (1) Acute pouchitis: <4 weeks symptoms, responsive to antibiotics; (2) Chronic antibiotic-dependent: recurrent requiring maintenance antibiotics or cycling; (3) Chronic antibiotic-refractory: failing 4+ weeks antibiotics—highest morbidity, pouch failure risk. Symptoms: increased stool frequency (from baseline 4–6 to >10/day), urgency, bloody stools, abdominal cramping, fever, extraintestinal flare. Diagnosis: PDAI (Pouchitis Disease Activity Index, 0–18, ≥7 = pouchitis) or modified PDAI based on pouchoscopy + biopsy. Endoscopy: erythema, edema, friability, ulceration of pouch mucosa; biopsy shows acute and chronic inflammation with variable architectural distortion. Rule out specific causes: cuffitis (inflammation of retained rectal cuff), Crohn's-like changes (granulomas, fistulas, proximal small bowel involvement—may reclassify as Crohn's-type pouchitis), CMV infection (immunocompromised patients), C. difficile (always test in resistant cases), NSAID-related, ischemic, or irritable pouch syndrome (normal pouchoscopy with symptoms—not pouchitis).
Always test for C. difficile in pouchitis, especially antibiotic-refractory cases—fecal microbiota shifts in the pouch make these patients vulnerable. Also consider cuffitis as a mimicker—endoscopic inspection of the cuff mucosa below the staple line is mandatory, with biopsies.
- 50% pouchitis by 5 years; 75% lifetime
- Classification: acute, chronic antibiotic-dependent, chronic refractory
- PDAI ≥7 defines pouchitis; pouchoscopy + biopsy essential
- Rule out: cuffitis, Crohn's-like, CMV, C. difficile, NSAID, IPS
- IPS = symptoms with normal pouch—functional, not pouchitis
3Pouchitis Treatment Algorithm
Acute pouchitis: first-line ciprofloxacin 500 mg BID × 2 weeks (superior to metronidazole in head-to-head trials); alternatives metronidazole 500 mg BID, rifaximin 400 mg TID, or combination. Response is typically rapid (within days). Chronic antibiotic-dependent: maintenance rotating antibiotics (2-week cycles alternating) or probiotics (VSL#3 /De Simone formulation 3600 billion CFU daily; evidence best for maintenance of remission). Chronic antibiotic-refractory: escalate to biologics—vedolizumab (EARNEST trial showed efficacy), ustekinumab, anti-TNF (infliximab, adalimumab)—treating as IBD. Consider budesonide foam/enema for distal pouchitis, oral budesonide for diffuse. Salvage: revise surgery for chronic cuffitis (cuff excision); pouch excision with permanent ileostomy is last resort. Referral to a Saudi tertiary center with dedicated pouch clinic (KFSHRC, KAMC) for complex cases. Cuffitis (common, missed): treat with mesalamine suppositories or budesonide foam first. Crohn's-like pouch disease: use Crohn's algorithm (biologics + smoking cessation + selective strictureplasty).
Chronic antibiotic-refractory pouchitis is increasingly treated as Crohn's-like biologic-responsive disease. Vedolizumab (EARNEST trial) is first-line biologic with favorable safety. Early referral to a specialized pouch clinic is crucial—these patients are complex and benefit from multidisciplinary care.
- Acute: ciprofloxacin 500 mg BID × 2 weeks first-line
- Chronic antibiotic-dependent: rotating antibiotics + VSL#3 probiotic
- Chronic refractory: vedolizumab (EARNEST), ustekinumab, anti-TNF
- Cuffitis: mesalamine suppository or budesonide foam
- Salvage: cuff excision or pouch excision with end ileostomy
4Pouch Surveillance, Fertility, Pregnancy
Pouch surveillance: annual pouchoscopy with biopsies from pouch body, ATZ (anal transition zone), and cuff for dysplasia monitoring in patients with: prior colonic dysplasia/cancer, PSC, chronic pouchitis, long pouch duration (>10 years). For pouchitis monitoring, PDAI or modified PDAI guides interval. Dysplasia management similar to UC: visible resectable → endoscopic; invisible multifocal or HGD → pouch excision. Fertility in women: TAC + IPAA reduces fertility (~30% reduction, largely due to pelvic adhesions affecting tubal function); discuss before surgery. Modern minimally invasive approaches may mitigate this. Options: (1) delay IPAA if fertility is priority (stay with end ileostomy); (2) robotic/laparoscopic IPAA with adhesion-reducing techniques. Pregnancy after IPAA: safe, though pouch function may temporarily worsen. Delivery mode: vaginal delivery acceptable for straightforward cases; C-section often preferred for complex pouches or if obstetric concern (discuss with pouch surgeon). In Saudi cultural context, fertility concerns are pronounced—engage spouses in counseling and consider referral to Saudi reproductive specialists for IVF planning when timing is urgent.
Saudi female IBD patients often prioritize fertility—discuss IPAA's fertility impact extensively, offer delayed reconstruction (permanent end ileostomy is viable for those planning family soon with reconstruction later), and refer to IVF specialists if urgent timing. Document these conversations thoroughly in the chart.
- Annual pouchoscopy for high-risk: PSC, prior dysplasia, chronic pouchitis, >10y pouch
- Dysplasia management mirrors UC (visible resect, invisible/HGD excise)
- IPAA reduces female fertility ~30%; laparoscopic/robotic may mitigate
- Pregnancy after IPAA safe; vaginal delivery acceptable with obstetric judgment
- Saudi context: prioritize fertility counseling; offer delayed reconstruction
- J-pouch is standard; staging depends on urgency (2-stage elective, 3-stage ASUC)
- Pouchitis lifetime risk 75%; diagnose with PDAI + pouchoscopy
- Chronic refractory pouchitis treated as IBD with vedolizumab first-line
- Annual pouchoscopy surveillance for high-risk subgroups
- Discuss fertility impact before IPAA; offer delayed reconstruction in Saudi patients
OR Observation: IBD Surgical Procedures
Live OR observation and structured debrief of common IBD operations: ileocecal resection, total abdominal colectomy, IPAA.
1Ileocecal Resection (Laparoscopic)
Observation focus: (1) pre-op planning review—MRE/CTE images, stricture length, penetrating features; (2) patient positioning (modified lithotomy or supine), port placement (4–5 ports: umbilical camera, RLQ, RUQ, LLQ working); (3) initial laparoscopic survey identifying disease extent, additional small bowel lesions (missed in imaging ~15%); (4) mobilization of right colon and terminal ileum from retroperitoneum; (5) mesenteric division—vascular control with staplers or energy devices; (6) bowel transection 2 cm proximal to visibly diseased terminal ileum and 2 cm distal on ascending colon (avoid excessive margin to preserve length); (7) anastomosis—Kono-S (preferred for IBD per emerging data), side-to-side stapled, or end-to-end hand-sewn; (8) specimen extraction via Pfannenstiel incision; (9) leak test if low anastomosis or concern; (10) closure. Observation discussion: strictureplasty decision if multifocal disease, preservation of ileocecal valve when possible, mesenteric lymphadenopathy (submit to pathology), incidental findings. Typical length 2–3 hours; LOS 3–5 days with ERAS.
Even with excellent imaging, intraoperative findings change the plan in ~20%. Trainees should note how the surgeon adapts (e.g., discovering unexpected proximal small bowel strictures may require strictureplasty rather than extended resection). Documentation of intraop findings is as important as the planned procedure.
- Pre-op MRE review; intraop survey finds additional disease in ~15%
- 4–5 ports laparoscopic; mobilize right colon + terminal ileum
- 2 cm margins; preserve ileocecal valve when possible
- Kono-S anastomosis preferred for IBD (reduces recurrence)
- Leak test for low anastomoses; ERAS reduces LOS to 3–5 days
2Total Abdominal Colectomy with End Ileostomy (Emergency)
For ASUC failing medical rescue or toxic megacolon, total abdominal colectomy (TAC) with end ileostomy and Hartmann closure of rectal stump (or long Hartmann for future IPAA) is standard. Observation focus: (1) emergency positioning and access—midline laparotomy for toxic megacolon (safer than laparoscopic), Pfannenstiel or umbilical in elective; (2) bowel handling—thin friable colon requires extreme care to avoid perforation; (3) division of mesentery staying close to bowel wall in preservation mode (leaving rectal mesentery for future IPAA); (4) rectal stump management—long Hartmann (close rectum at sacral promontory) preserves length for pouch, versus short Hartmann (rectum closed at peritoneal reflection) for critically ill; (5) rectal stump mucous fistula or closed with drain; (6) end ileostomy at preoperatively marked site, matured immediately with Brooke eversion for skin level; (7) copious lavage, drain placement, closure with tension-free fascia. Discussion: timing of subsequent IPAA (3–6 months after stabilization, nutrition recovery, steroid tapering); importance of not extending resection beyond necessary for future reconstruction.
Toxic megacolon surgery is a high-stakes case—prioritize patient stabilization over elegance. Preserve rectal mesentery and length for future reconstruction; never resect the rectum in emergency unless absolutely necessary. Communication between emergency team, gastroenterology, and surgery is essential.
- Midline laparotomy for toxic megacolon; preserve rectal length for future IPAA
- Long Hartmann closure at sacral promontory (vs short at peritoneal reflection)
- Preoperative stoma marking critical even in emergency when possible
- Mesentery division close to bowel wall preserves vessels for reconstruction
- IPAA typically 3–6 months later after stabilization and nutrition recovery
3IPAA Construction
Completion proctectomy + IPAA construction (stage 2 of 2-stage, or stage 2 of 3-stage). Observation focus: (1) take-down of adhesions from prior surgery; (2) completion proctectomy—staying within mesorectal plane, preserving pelvic autonomic nerves for continence and sexual function; (3) pelvic dissection to levator ani; (4) rectal transection at ATZ—stapled close to dentate line (1–2 cm cuff) or handsewn after mucosectomy; (5) mobilization of small bowel and mesentery to reach pelvis—lengthening maneuvers (ileocolic artery division, mesenteric peritoneum incisions, Kocher maneuver); (6) J-pouch construction—two 15 cm limbs of distal ileum stapled or hand-sewn; (7) anastomosis—circular stapled IPAA with anvil in pouch apex and gun through anus; (8) leak test; (9) diverting loop ileostomy placement; (10) drain, closure. Discussion with surgeon: nerve preservation (Denonvilliers fascia, hypogastric nerves), anastomotic tension (if pouch doesn't reach, consider splenic flexure take-down or small bowel lengthening); stapled vs hand-sewn rationale.
Pouch tension is the most common cause of anastomotic leak. If the surgeon cannot achieve tension-free reach to the dentate line, recognize this as a critical moment requiring lengthening maneuvers—not just pulling harder. Observation of these decision points is invaluable for fellows.
- Nerve preservation (Denonvilliers, hypogastric) critical for continence and sexual function
- Stapled IPAA preserves 1–2 cm cuff; hand-sewn after mucosectomy for dysplasia
- Pouch reach without tension required; lengthening maneuvers if needed
- Diverting loop ileostomy standard (closure ~3 months later)
- Leak test: confirms integrity before abdominal closure
4Structured Debrief & Trainee Reflection
After each OR case, structured debrief of 20 minutes covers: (1) indications reviewed by trainee—confirming they understood why surgery was chosen; (2) technical findings differ from preoperative imaging; (3) surgeon's critical decision points (e.g., strictureplasty vs resection, pouch design, diverting ostomy); (4) complications avoided or encountered and their management; (5) expected postoperative course and follow-up plan; (6) trainee reflection: what would they have done differently, what questions remain. Trainees maintain a surgical logbook documenting cases observed, procedures, outcomes, and learning points—required for fellowship certification. Encourage trainees to present one case at IBD MDT the following week, integrating the surgical perspective with their gastroenterology management.
A surgical logbook integrated with the gastroenterology fellowship portfolio provides tangible evidence of trainee development and is increasingly required by Saudi Commission for Health Specialties (SCFHS) credentialing bodies. Structured reflection also builds clinical judgment beyond technical observation.
- Structured 20-minute debrief after each observed case
- Cover indications, intraop findings, decisions, complications, follow-up
- Trainee reflection is critical for judgment development
- Surgical logbook required for SCFHS fellowship credentialing
- Present one surgical case at IBD MDT to integrate perspectives
- Ileocecal resection: 2 cm margins, Kono-S anastomosis, laparoscopic preferred
- Emergency TAC: preserve rectal length for future IPAA; long Hartmann
- IPAA: nerve preservation, tension-free pouch reach, leak test mandatory
- Structured debrief and surgical logbook integrate fellowship learning
- Present surgical cases at IBD MDT to synthesize gastroenterology + surgery perspectives
Post-Surgical Complications & Recurrence Prevention
Early and late complications after IBD surgery, postoperative recurrence in Crohn's, and evidence-based prevention strategies.
1Early Complications: Leak, Infection, Ileus
Anastomotic leak (1–5% ileocolic, 5–15% IPAA): presents with fever, abdominal pain, drainage from wound/drain, tachycardia, ileus at days 3–10 post-op. Diagnose: CT with rectal/oral contrast; water-soluble contrast enema for IPAA. Management: contained small leak → NPO, IV antibiotics, drainage catheter; large/uncontrolled → surgical exploration, lavage, diverting stoma. Wound infection (5–20%): local care, possibly NPWT (negative pressure wound therapy); antibiotics if cellulitis or systemic signs. Intra-abdominal abscess: percutaneous drainage first-line. Postoperative ileus: prolonged (>4–5 days) is most common non-infectious complication—multimodal analgesia avoiding opioids, chewing gum, early mobilization, consider alvimopan in select cases. SSI prevention bundle: preoperative chlorhexidine bath, clippers not razors, appropriate antibiotics (usually cefazolin + metronidazole or ertapenem) within 60 min of incision, maintain normothermia and normoglycemia, wound protector, oral abx + mechanical prep for colorectal. VTE events presenting early: immediate anticoagulation after leak/bleeding ruled out.
Early anastomotic leak after IPAA can be devastating—low threshold for CT at any clinical change (fever, tachycardia, ileus, drainage). Saudi tertiary centers should have interventional radiology available for percutaneous drainage 24/7 of contained leaks—this is often pouch-preserving.
- Leak rates: 1–5% ileocolic, 5–15% IPAA; present days 3–10 post-op
- CT with contrast for diagnosis; contained leak → percutaneous drainage
- SSI bundle: chlorhexidine, clippers, timely abx, normothermia, glucose control
- Prolonged ileus common—opioid-sparing analgesia, mobilization
- Early VTE events: anticoagulate after excluding surgical bleeding
2Late Complications: Stricture, Fistula, Hernia, Adhesions
Anastomotic stricture: common late complication of bowel anastomosis (10–20% at ileocolic anastomosis by 5 years). Presentation: obstruction symptoms (cramping, distension, vomiting), weight loss. Management: endoscopic balloon dilation first-line (covered in Month 7); surgical revision for refractory. Fistula (to skin, bladder, vagina, bowel): late fistulas often indicate recurrent Crohn's—image first, then medical therapy + endoscopic/surgical as needed. Incisional hernia: 10–20% of laparotomy patients; mesh repair when symptomatic. Adhesive small bowel obstruction: 20–30% lifetime risk after abdominal surgery; partial obstruction → NG decompression, IV fluids, watchful waiting; complete obstruction or strangulation signs → surgery. Pouch-specific late: pouch-vaginal fistula (management complex—combination of diversion + medical therapy + surgical revision), anastomotic stenosis (dilation or revision), pouch prolapse (surgical), pelvic sepsis after late leak. Short bowel syndrome: after extensive resections in Crohn's—address with micronutrient supplementation, low-fat diet for steatorrhea, cholestyramine for bile salt diarrhea, teduglutide for severe SBS.
Pouch-vaginal fistula is devastating to quality of life—early multidisciplinary management at a specialized pouch center is essential. Saudi patients may present late due to cultural reluctance to discuss—create a safe clinical environment with female pouch nurses and Arabic-speaking counselors.
- Anastomotic stricture: EBD first-line (covered in Month 7)
- Late fistula = likely Crohn's recurrence; image + medical + surgical
- Incisional hernia 10–20%; mesh repair when symptomatic
- Adhesive SBO: 20–30% lifetime risk; partial managed conservatively
- Pouch-vaginal fistula: multidisciplinary center; cultural sensitivity
3Crohn's Postoperative Recurrence: Risk Stratification & Prevention
Without prevention, Crohn's recurs endoscopically in 60–80% at 1 year, clinically in 20–30% at 1 year, and 50% need re-operation at 10 years. Risk factors: smoking (strongest modifiable), prior bowel resection (esp. 2+), penetrating disease, perianal disease, young age at diagnosis, extensive small bowel involvement. POCER algorithm: perform colonoscopy at 6 months post-op regardless of symptoms. If Rutgeerts i0–i1 (≤5 aphthae): no change in therapy. If i2 (>5 aphthae or anastomotic inflammation; specifically i2b in neoterminal ileum): escalate—start biologic (anti-TNF preferred per POCER) or intensify existing. If i3–i4: escalate aggressively with biologic + immunomodulator. Preventive options: (1) smoking cessation — #1 intervention, reduces recurrence 2-fold; (2) metronidazole 3 months — marginal effect; (3) thiopurines — modest benefit; (4) biologics (anti-TNF, vedolizumab, ustekinumab) — strongest; start within 4 weeks post-op for high-risk patients. REMIND and PREVENT-CD trials support anti-TNF. Saudi-specific: address smoking aggressively (higher male smoking rates in KSA); provide shisha cessation counseling (shisha is particularly recurrence-promoting).
Postoperative colonoscopy at 6 months is the lynchpin of recurrence prevention. Implement a "POCER protocol" at your institution: scheduled at time of discharge with patient education that "surgery is not a cure for Crohn's; we will need to scope in 6 months." Smoking cessation should be revisited at every visit.
- Recurrence: endoscopic 60–80% at 1y, clinical 20–30%, re-op 50% at 10y
- POCER: colonoscopy at 6 months; Rutgeerts ≥i2b → escalate to biologic
- Smoking cessation is #1 modifiable risk factor (shisha counts)
- High-risk patients: start biologic within 4 weeks post-op
- Saudi: address shisha/tobacco cessation aggressively
4Ostomy Management & Patient Quality of Life
Patients with end ileostomy or loop ileostomy require ongoing support: stoma nurse specialist follow-up at 2 weeks, 6 weeks, 3 months post-op; troubleshoot leaks, skin irritation, peristomal hernias, high output. High-output stoma (>1.5 L/day): loperamide 2–4 mg QID, bulk-forming agents, PPI, careful fluid/electrolyte management—hospitalization if dehydration or electrolyte derangement. Education: bag changes, appliance selection, skin care, nutrition, activity (most activities fine; contact sports discuss; swimming possible with appropriate appliance), travel (carry extra supplies, medication letter for customs—important for Saudi patients traveling to Hajj or abroad), body image, intimacy. Psychological support: ileostomy is life-changing; depression/anxiety common—screen and refer. Peer support groups (Saudi Ostomy Association if available, regional chapters). Hajj/Umrah with stoma: patient may perform hajj; practical considerations include larger-volume bag for limited changes, supply pack, hajj-specific supplies available from Saudi ostomy vendors. Arabic-language educational materials from Saudi Commission for Health Specialties and industry partners (Hollister, ConvaTec, Coloplast Arabic materials available).
Proactively prepare Saudi patients for Hajj/Umrah with a stoma: written plan in Arabic, stoma supplies pack appropriate for ihram, dietary guidance for desert travel, contact information for Saudi ostomy support during the journey. Most patients can perform Hajj successfully with preparation.
- Stoma nurse follow-up at 2, 6 weeks, 3 months post-op
- High-output stoma: loperamide, fluid/electrolyte management, hospitalize if severe
- Educate: bag changes, skin care, nutrition, activity, travel, intimacy
- Psychological support and peer groups essential
- Saudi: Hajj/Umrah preparation with Arabic materials and stoma supplies
- Early leak after IPAA: low CT threshold; percutaneous drainage often pouch-preserving
- POCER protocol: 6-month colonoscopy drives Crohn's recurrence prevention
- Smoking cessation (including shisha) is the #1 recurrence prevention
- High-risk Crohn's post-op: start biologic within 4 weeks
- Comprehensive ostomy support including Hajj/Umrah preparation for Saudi patients
Assessment
Perioperative management plan presentation + Pouchitis diagnostic OSCE
Clinical Pearls
Continue vedolizumab perioperatively — it does NOT increase surgical complications
Nutritional optimization (albumin >3.0 g/dL) reduces wound complications by ~50%
3-stage IPAA is safest for ASUC patients on high-dose steroids
Female fertility may decrease after IPAA — laparoscopic approach preserves fertility better
Practice Points
Create a perioperative IBD checklist: meds, nutrition, VTE, wound care, stoma education
Post-colectomy: start anti-TNF prophylaxis within 2-4 weeks if high-risk features
Ensure stoma nurse education before discharge — poor stoma care is #1 readmission cause
Key References
Bemelman WA, et al. ECCO-ESCP Consensus on Surgery for CD. J Crohns Colitis. 2018;12:1-16
Nguyen GC, et al. AGA Update: Perioperative Management in IBD. Gastroenterology. 2021;161:e55-e66
Shen B, et al. Pouchitis: diagnosis and management. Curr Opin Gastroenterol. 2022;38:351-361
Reading List
ECCO-ESCP Surgery Consensus for CD
Bemelman WA, et al. — J Crohns Colitis (2018)
AGA Update on Perioperative IBD Management
Nguyen GC, et al. — Gastroenterology (2021)
IPAA: outcomes and quality of life
Fazio VW, et al. — Ann Surg (2013)
Pouchitis: pathophysiology and management
Shen B, et al. — Inflamm Bowel Dis (2022)
